The estimated Net Worth of Andrew J Murphy is at least $91.7 Million dollars as of 13 August 2024. Mr. Murphy owns over 20,000 units of Regeneron Pharmaceuticals stock worth over $77,967,884 and over the last 5 years he sold REGN stock worth over $4,234,962. In addition, he makes $9,519,350 as Executive Vice President - Research at Regeneron Pharmaceuticals.
Sign up
Mr. Murphy REGN stock SEC Form 4 insiders trading
Andrew has made over 15 trades of the Regeneron Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of REGN stock worth $7,993,200 on 13 August 2024.
The largest trade he's ever made was exercising 20,000 units of Regeneron Pharmaceuticals stock on 13 August 2024 worth over $7,993,200. On average, Andrew trades about 8,495 units every 72 days since 2019. As of 13 August 2024 he still owns at least 68,306 units of Regeneron Pharmaceuticals stock.
You can see the complete history of Mr. Murphy stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Andrew Murphy biography
Andrew J. Murphy serves as Executive Vice President - Research of the Company since January 2019. He previously served as Senior Vice President, Research, Regeneron Laboratories from January 2013 to December 2018, as Vice President, Target Discovery from May 2005 to December 2012, as Vice President, Gene Discovery and Bioinformatics from January 2001 to May 2005, and Director of Genomics and Bioinformatics from May 1999 to December 2000. Dr. Murphy is a co-inventor of several of the Company’s key technologies, including VelociGene and VelocImmune, and continues to lead several technology centers and therapeutic focus areas. He received his B.S. in Molecular Biology at the University of Wisconsin, and his Ph.D. in Human Genetics from Columbia University, College of Physicians and Surgeons.
What is the salary of Andrew Murphy?
As the Executive Vice President - Research of Regeneron Pharmaceuticals, the total compensation of Andrew Murphy at Regeneron Pharmaceuticals is $9,519,350. There are 4 executives at Regeneron Pharmaceuticals getting paid more, with P. Roy Vagelos having the highest compensation of $22,304,300.
How old is Andrew Murphy?
Andrew Murphy is 62, he's been the Executive Vice President - Research of Regeneron Pharmaceuticals since 2019. There are 9 older and 14 younger executives at Regeneron Pharmaceuticals. The oldest executive at Regeneron Pharmaceuticals, Inc. is P. Roy Vagelos, 90, who is the Chairman of the Board, Director.
Insiders trading at Regeneron Pharmaceuticals
Over the last 22 years, insiders at Regeneron Pharmaceuticals have traded over $13,084,686,326 worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth $2,539,854,760 . The most active insiders traders include Sanofi, Pharma Ag Novartis, and Leonard S Schleifer. On average, Regeneron Pharmaceuticals executives and independent directors trade stock every 8 days with the average trade being worth of $47,694,347. The most recent stock trade was executed by Marion Mc Court on 3 September 2024, trading 1,000 units of REGN stock currently worth $381,400.
What does Regeneron Pharmaceuticals do?
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
What does Regeneron Pharmaceuticals's logo look like?
Complete history of Mr. Murphy stock trades at Regeneron Pharmaceuticals
Regeneron Pharmaceuticals executives and stock owners
Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include:
-
P. Roy Vagelos,
Chairman of the Board, Director -
Leonard Schleifer,
President, Chief Executive Officer, Director -
George Yancopoulos,
President, Chief Scientific Officer, Director -
Marion McCourt,
Senior Vice President - Commercial -
Andrew Murphy,
Executive Vice President - Research -
Neil Stahl,
Executive Vice President - Research and Development -
Robert Landry,
Chief Financial Officer, Executive Vice President - Finance -
Daniel Van Plew,
Executive Vice President, General Manager - Industrial Operations and Product Supply -
Dr. George D. Yancopoulos M.D., Ph.D.,
Scientific Founder, Pres, Chief Scientific Officer & Director -
Dr. Leonard S. Schleifer M.D., Ph.D.,
Founder, Pres, CEO & Director -
Dr. George D. Yancopoulos,
Scientific Founder, Pres, Chief Scientific Officer & Director -
Robert E. Landry Jr.,
Exec. VP of Fin. & CFO -
Daniel P. Van Plew,
Exec. VP and GM of Industrial Operations & Product Supply -
Joseph J. LaRosa,
Exec. VP, Gen. Counsel & Sec. -
Dr. Andrew J. Murphy,
Exec. VP of Research -
Arthur Ryan,
Independent Director -
George Sing,
Independent Director -
Christine Poon,
Independent Director -
Michael Brown,
Independent Director -
Huda Zoghbi,
Independent Director -
Joseph Goldstein,
Independent Director -
Bonnie Bassler,
Independent Director -
N. Anthony Coles,
Independent Director -
Marc Tessier-Lavigne,
Independent Director -
Christopher Fenimore,
Vice President, Controller -
Joseph LaRosa,
Executive Vice President, General Counsel, Secretary -
Justin Holko,
VP of Investor Relations -
Bob McCowan,
Sr. VP of IT & Chief Information Officer -
Gerald Underwood,
Sr. VP of Technical Operations -
Christopher R. Fenimore,
Sr. VP, Head of Accounting & Controller -
Patrice Gilooly,
Sr. VP of Quality Assurance & Operations -
Charles A Baker,
Director -
Michael S Aberman,
SVP Strategy Investor Relation -
Sanofi,
-
Robert J Terifay,
EVP Commercial -
Alfred G Gilman,
Director -
Robert Alexander Ingram,
Director -
Eric M Shooter,
Director -
Murray A Goldberg,
SVP Administration & Asst Secr -
Stuart Kolinski,
SVP General Counsel and Secret -
Amerique Du Nord S.N.C. San...,
-
Peter Dworkin,
VP Investor Relations & Commun -
Randall Rupp,
SVP, Manufuring Operations -
Pharma Ag Novartis,
10% owner -
Hans Peter Guler,
VP Clinical Programs -
William Roberts,
VP Reg Dev & Med Safety -
Peter Powchik,
SVP Clinical Development & Reg -
Douglas S Mc Corkle,
VP Controller and Asst Treasur -
Craig B. Thompson,
Director -
Kathryn Guarini,
Director -
David P Schenkein,
Director -
Jason Pitofsky,
VP Controller